ARGX vs. SMMT: argenx vs. Summit Therapeutics Stock Comparison

Company Profile

argenx (ARGX) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Summit Therapeutics (SMMT) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. argenx (ARGX) has a non-negative beta of 0.45.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

argenx (ARGX) has no ROE value reported for this period; Summit Therapeutics (SMMT) reports a negative figure of -220.01%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: argenx (ARGX) reports revenue growth of 89.64%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Summit Therapeutics (SMMT) shows current ratio of 5.99 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Summit Therapeutics (SMMT) at 0.04 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for argenx (ARGX), whose P/S ratio of 9.86 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Measured against book value, both argenx (ARGX) at 172.23 and Summit Therapeutics (SMMT) at 23.13 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics